How to Select the Right Cost-Effectiveness Model?: A Systematic Review and Stepwise Approach for Selecting a Transferable Health Economic Evaluation Model for Rheumatoid Arthritis

Objective In the current study, we propose an approach for selection of a model that is transferable to a specific decision-making context (in this case, the Netherlands), using the case of rheumatoid arthritis (RA). The objectives of this study were (a) to perform a systematic literature review to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PharmacoEconomics 2014-05, Vol.32 (5), p.429-442
Hauptverfasser: van Haalen, H. G. M., Severens, J. L., Tran-Duy, A., Boonen, A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 442
container_issue 5
container_start_page 429
container_title PharmacoEconomics
container_volume 32
creator van Haalen, H. G. M.
Severens, J. L.
Tran-Duy, A.
Boonen, A.
description Objective In the current study, we propose an approach for selection of a model that is transferable to a specific decision-making context (in this case, the Netherlands), using the case of rheumatoid arthritis (RA). The objectives of this study were (a) to perform a systematic literature review to identify existing health economic evaluation models for economic evaluation of disease-modifying antirheumatic drugs (DMARDs) in RA; and (b) to test the appropriateness of a stepwise model-selection process. Methods First, we searched Medline and Embase to identify relevant studies in the English language, published between 1 January 2002 and 31 August 2012. From the included studies, all unique models were identified. Second, we applied a multi-step approach to model selection. Models that did not meet all minimal methodological and structural requirements based on the Outcome Measures in Rheumatology (OMERACT) criteria were excluded. Next, models were assessed on the basis of their fit when transferred to the Dutch health care setting. The criteria for model fit were transferability factors, as published by Welte et al., after exclusion of those that were deemed transferable by simple adaptation. Finally, the remaining models underwent a general quality check using the Philips checklist. Models showing good fit and high quality were considered to be transferable to the Dutch health care setting, using simple adaptation. Results The systematic literature search identified 498 articles, which included 33 unique health economic evaluation models. Only six models passed the minimal methodological and structural requirements. Two of these models had an imperfect transferability fit to the Dutch health care setting, according to the Welte method. The remaining four models were, according to the Philips method, of good quality and were expected to be transferable by a simple adaptation. Conclusion This study introduces a stepwise approach for selecting health economic evaluation models that are transferable by a simple adaptation. The approach seems feasible and can be applied in various therapeutic areas, provided that the minimal methodological and structural requirements are defined accordingly. Availability of health economic evaluation models coupled with structured model selection could improve the efficiency, quality and comparability of health economic research.
doi_str_mv 10.1007/s40273-014-0139-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1523406325</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1523406325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2699-44fd9e36630b0767bacaa23b6d2e120d10774de10617b8963216c02bba61abab3</originalsourceid><addsrcrecordid>eNp1kF1LwzAUhoMobn78AG-kIII31XOSNFmuRMZ0wkTw4zokbbp1dO1sWsV_b-bmB4IXIeHkOSdvHkKOEM4RQF54DlSyGJCHxVSstkgfUaqYhvr25xliKRT0yJ73cwAQTNJd0qM8AT5IWJ_guH6L2jp6dKVL26idueihmM7aaFj7Nh7leagWr65y3kd3debKywOyk5vSu8PNvk-er0dPw3E8ub-5HV5N4pQKpWLO80w5JgQDC1JIa1JjKLMiow4pZAhS8swhCJR2oASjKFKg1hqBxhrL9snZeu6yqV8651u9KHzqytJUru68xoQyHj5Ek4Ce_EHndddUIZ1GQRkLkMRA4ZpKm9r7xuV62RQL07xrBL3yqdc-dfCpVz61Cj3Hm8mdXbjsu-NLYABON4DxqSnzxlRp4X-4QQKCJquIdM35cFVNXfMr4r-vfwBTNIlc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1623363271</pqid></control><display><type>article</type><title>How to Select the Right Cost-Effectiveness Model?: A Systematic Review and Stepwise Approach for Selecting a Transferable Health Economic Evaluation Model for Rheumatoid Arthritis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>van Haalen, H. G. M. ; Severens, J. L. ; Tran-Duy, A. ; Boonen, A.</creator><creatorcontrib>van Haalen, H. G. M. ; Severens, J. L. ; Tran-Duy, A. ; Boonen, A.</creatorcontrib><description>Objective In the current study, we propose an approach for selection of a model that is transferable to a specific decision-making context (in this case, the Netherlands), using the case of rheumatoid arthritis (RA). The objectives of this study were (a) to perform a systematic literature review to identify existing health economic evaluation models for economic evaluation of disease-modifying antirheumatic drugs (DMARDs) in RA; and (b) to test the appropriateness of a stepwise model-selection process. Methods First, we searched Medline and Embase to identify relevant studies in the English language, published between 1 January 2002 and 31 August 2012. From the included studies, all unique models were identified. Second, we applied a multi-step approach to model selection. Models that did not meet all minimal methodological and structural requirements based on the Outcome Measures in Rheumatology (OMERACT) criteria were excluded. Next, models were assessed on the basis of their fit when transferred to the Dutch health care setting. The criteria for model fit were transferability factors, as published by Welte et al., after exclusion of those that were deemed transferable by simple adaptation. Finally, the remaining models underwent a general quality check using the Philips checklist. Models showing good fit and high quality were considered to be transferable to the Dutch health care setting, using simple adaptation. Results The systematic literature search identified 498 articles, which included 33 unique health economic evaluation models. Only six models passed the minimal methodological and structural requirements. Two of these models had an imperfect transferability fit to the Dutch health care setting, according to the Welte method. The remaining four models were, according to the Philips method, of good quality and were expected to be transferable by a simple adaptation. Conclusion This study introduces a stepwise approach for selecting health economic evaluation models that are transferable by a simple adaptation. The approach seems feasible and can be applied in various therapeutic areas, provided that the minimal methodological and structural requirements are defined accordingly. Availability of health economic evaluation models coupled with structured model selection could improve the efficiency, quality and comparability of health economic research.</description><identifier>ISSN: 1170-7690</identifier><identifier>EISSN: 1179-2027</identifier><identifier>DOI: 10.1007/s40273-014-0139-9</identifier><identifier>PMID: 24504853</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antirheumatic Agents - administration &amp; dosage ; Antirheumatic Agents - economics ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - economics ; Biological and medical sciences ; Bones, joints and connective tissue. Antiinflammatory agents ; Cost-Benefit Analysis ; Decision Making ; Decision Support Techniques ; Diseases of the osteoarticular system ; Drugs ; Economic models ; Health Administration ; Health Care Costs ; Health Economics ; Health technology assessment ; Humans ; Inflammatory joint diseases ; Jurisdiction ; Literature reviews ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Models, Economic ; Netherlands ; Pharmacoeconomics and Health Outcomes ; Pharmacology. Drug treatments ; Prescription drugs ; Public Health ; Quality of Life Research ; Rheumatoid arthritis ; Studies ; Systematic Review</subject><ispartof>PharmacoEconomics, 2014-05, Vol.32 (5), p.429-442</ispartof><rights>Springer International Publishing Switzerland 2014</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Wolters Kluwer Health Adis International May 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2699-44fd9e36630b0767bacaa23b6d2e120d10774de10617b8963216c02bba61abab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40273-014-0139-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40273-014-0139-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28506255$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24504853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Haalen, H. G. M.</creatorcontrib><creatorcontrib>Severens, J. L.</creatorcontrib><creatorcontrib>Tran-Duy, A.</creatorcontrib><creatorcontrib>Boonen, A.</creatorcontrib><title>How to Select the Right Cost-Effectiveness Model?: A Systematic Review and Stepwise Approach for Selecting a Transferable Health Economic Evaluation Model for Rheumatoid Arthritis</title><title>PharmacoEconomics</title><addtitle>PharmacoEconomics</addtitle><addtitle>Pharmacoeconomics</addtitle><description>Objective In the current study, we propose an approach for selection of a model that is transferable to a specific decision-making context (in this case, the Netherlands), using the case of rheumatoid arthritis (RA). The objectives of this study were (a) to perform a systematic literature review to identify existing health economic evaluation models for economic evaluation of disease-modifying antirheumatic drugs (DMARDs) in RA; and (b) to test the appropriateness of a stepwise model-selection process. Methods First, we searched Medline and Embase to identify relevant studies in the English language, published between 1 January 2002 and 31 August 2012. From the included studies, all unique models were identified. Second, we applied a multi-step approach to model selection. Models that did not meet all minimal methodological and structural requirements based on the Outcome Measures in Rheumatology (OMERACT) criteria were excluded. Next, models were assessed on the basis of their fit when transferred to the Dutch health care setting. The criteria for model fit were transferability factors, as published by Welte et al., after exclusion of those that were deemed transferable by simple adaptation. Finally, the remaining models underwent a general quality check using the Philips checklist. Models showing good fit and high quality were considered to be transferable to the Dutch health care setting, using simple adaptation. Results The systematic literature search identified 498 articles, which included 33 unique health economic evaluation models. Only six models passed the minimal methodological and structural requirements. Two of these models had an imperfect transferability fit to the Dutch health care setting, according to the Welte method. The remaining four models were, according to the Philips method, of good quality and were expected to be transferable by a simple adaptation. Conclusion This study introduces a stepwise approach for selecting health economic evaluation models that are transferable by a simple adaptation. The approach seems feasible and can be applied in various therapeutic areas, provided that the minimal methodological and structural requirements are defined accordingly. Availability of health economic evaluation models coupled with structured model selection could improve the efficiency, quality and comparability of health economic research.</description><subject>Antirheumatic Agents - administration &amp; dosage</subject><subject>Antirheumatic Agents - economics</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - economics</subject><subject>Biological and medical sciences</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Cost-Benefit Analysis</subject><subject>Decision Making</subject><subject>Decision Support Techniques</subject><subject>Diseases of the osteoarticular system</subject><subject>Drugs</subject><subject>Economic models</subject><subject>Health Administration</subject><subject>Health Care Costs</subject><subject>Health Economics</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Inflammatory joint diseases</subject><subject>Jurisdiction</subject><subject>Literature reviews</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Models, Economic</subject><subject>Netherlands</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Pharmacology. Drug treatments</subject><subject>Prescription drugs</subject><subject>Public Health</subject><subject>Quality of Life Research</subject><subject>Rheumatoid arthritis</subject><subject>Studies</subject><subject>Systematic Review</subject><issn>1170-7690</issn><issn>1179-2027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kF1LwzAUhoMobn78AG-kIII31XOSNFmuRMZ0wkTw4zokbbp1dO1sWsV_b-bmB4IXIeHkOSdvHkKOEM4RQF54DlSyGJCHxVSstkgfUaqYhvr25xliKRT0yJ73cwAQTNJd0qM8AT5IWJ_guH6L2jp6dKVL26idueihmM7aaFj7Nh7leagWr65y3kd3debKywOyk5vSu8PNvk-er0dPw3E8ub-5HV5N4pQKpWLO80w5JgQDC1JIa1JjKLMiow4pZAhS8swhCJR2oASjKFKg1hqBxhrL9snZeu6yqV8651u9KHzqytJUru68xoQyHj5Ek4Ce_EHndddUIZ1GQRkLkMRA4ZpKm9r7xuV62RQL07xrBL3yqdc-dfCpVz61Cj3Hm8mdXbjsu-NLYABON4DxqSnzxlRp4X-4QQKCJquIdM35cFVNXfMr4r-vfwBTNIlc</recordid><startdate>201405</startdate><enddate>201405</enddate><creator>van Haalen, H. G. M.</creator><creator>Severens, J. L.</creator><creator>Tran-Duy, A.</creator><creator>Boonen, A.</creator><general>Springer International Publishing</general><general>Adis International</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>4T-</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201405</creationdate><title>How to Select the Right Cost-Effectiveness Model?</title><author>van Haalen, H. G. M. ; Severens, J. L. ; Tran-Duy, A. ; Boonen, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2699-44fd9e36630b0767bacaa23b6d2e120d10774de10617b8963216c02bba61abab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antirheumatic Agents - administration &amp; dosage</topic><topic>Antirheumatic Agents - economics</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - economics</topic><topic>Biological and medical sciences</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Cost-Benefit Analysis</topic><topic>Decision Making</topic><topic>Decision Support Techniques</topic><topic>Diseases of the osteoarticular system</topic><topic>Drugs</topic><topic>Economic models</topic><topic>Health Administration</topic><topic>Health Care Costs</topic><topic>Health Economics</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Inflammatory joint diseases</topic><topic>Jurisdiction</topic><topic>Literature reviews</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Models, Economic</topic><topic>Netherlands</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Pharmacology. Drug treatments</topic><topic>Prescription drugs</topic><topic>Public Health</topic><topic>Quality of Life Research</topic><topic>Rheumatoid arthritis</topic><topic>Studies</topic><topic>Systematic Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Haalen, H. G. M.</creatorcontrib><creatorcontrib>Severens, J. L.</creatorcontrib><creatorcontrib>Tran-Duy, A.</creatorcontrib><creatorcontrib>Boonen, A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>PharmacoEconomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Haalen, H. G. M.</au><au>Severens, J. L.</au><au>Tran-Duy, A.</au><au>Boonen, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How to Select the Right Cost-Effectiveness Model?: A Systematic Review and Stepwise Approach for Selecting a Transferable Health Economic Evaluation Model for Rheumatoid Arthritis</atitle><jtitle>PharmacoEconomics</jtitle><stitle>PharmacoEconomics</stitle><addtitle>Pharmacoeconomics</addtitle><date>2014-05</date><risdate>2014</risdate><volume>32</volume><issue>5</issue><spage>429</spage><epage>442</epage><pages>429-442</pages><issn>1170-7690</issn><eissn>1179-2027</eissn><abstract>Objective In the current study, we propose an approach for selection of a model that is transferable to a specific decision-making context (in this case, the Netherlands), using the case of rheumatoid arthritis (RA). The objectives of this study were (a) to perform a systematic literature review to identify existing health economic evaluation models for economic evaluation of disease-modifying antirheumatic drugs (DMARDs) in RA; and (b) to test the appropriateness of a stepwise model-selection process. Methods First, we searched Medline and Embase to identify relevant studies in the English language, published between 1 January 2002 and 31 August 2012. From the included studies, all unique models were identified. Second, we applied a multi-step approach to model selection. Models that did not meet all minimal methodological and structural requirements based on the Outcome Measures in Rheumatology (OMERACT) criteria were excluded. Next, models were assessed on the basis of their fit when transferred to the Dutch health care setting. The criteria for model fit were transferability factors, as published by Welte et al., after exclusion of those that were deemed transferable by simple adaptation. Finally, the remaining models underwent a general quality check using the Philips checklist. Models showing good fit and high quality were considered to be transferable to the Dutch health care setting, using simple adaptation. Results The systematic literature search identified 498 articles, which included 33 unique health economic evaluation models. Only six models passed the minimal methodological and structural requirements. Two of these models had an imperfect transferability fit to the Dutch health care setting, according to the Welte method. The remaining four models were, according to the Philips method, of good quality and were expected to be transferable by a simple adaptation. Conclusion This study introduces a stepwise approach for selecting health economic evaluation models that are transferable by a simple adaptation. The approach seems feasible and can be applied in various therapeutic areas, provided that the minimal methodological and structural requirements are defined accordingly. Availability of health economic evaluation models coupled with structured model selection could improve the efficiency, quality and comparability of health economic research.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>24504853</pmid><doi>10.1007/s40273-014-0139-9</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1170-7690
ispartof PharmacoEconomics, 2014-05, Vol.32 (5), p.429-442
issn 1170-7690
1179-2027
language eng
recordid cdi_proquest_miscellaneous_1523406325
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Antirheumatic Agents - administration & dosage
Antirheumatic Agents - economics
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - economics
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Cost-Benefit Analysis
Decision Making
Decision Support Techniques
Diseases of the osteoarticular system
Drugs
Economic models
Health Administration
Health Care Costs
Health Economics
Health technology assessment
Humans
Inflammatory joint diseases
Jurisdiction
Literature reviews
Medical sciences
Medicine
Medicine & Public Health
Models, Economic
Netherlands
Pharmacoeconomics and Health Outcomes
Pharmacology. Drug treatments
Prescription drugs
Public Health
Quality of Life Research
Rheumatoid arthritis
Studies
Systematic Review
title How to Select the Right Cost-Effectiveness Model?: A Systematic Review and Stepwise Approach for Selecting a Transferable Health Economic Evaluation Model for Rheumatoid Arthritis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T04%3A25%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20to%20Select%20the%20Right%20Cost-Effectiveness%20Model?:%20A%20Systematic%20Review%20and%20Stepwise%20Approach%20for%20Selecting%20a%20Transferable%20Health%20Economic%20Evaluation%20Model%20for%20Rheumatoid%20Arthritis&rft.jtitle=PharmacoEconomics&rft.au=van%20Haalen,%20H.%20G.%20M.&rft.date=2014-05&rft.volume=32&rft.issue=5&rft.spage=429&rft.epage=442&rft.pages=429-442&rft.issn=1170-7690&rft.eissn=1179-2027&rft_id=info:doi/10.1007/s40273-014-0139-9&rft_dat=%3Cproquest_cross%3E1523406325%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1623363271&rft_id=info:pmid/24504853&rfr_iscdi=true